Market news

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T

General Dynamics (NYSE:GD) received a new multi year U.S. Army contract modification for Double V Hull A1 Stryker vehicles, extending through 2028. The award enlarges the Army Stryker program backlog and adds funded production for upgraded armored vehicles across multiple brigade combat teams. The contract update supports continued manufacturing at General Dynamics Land Systems facilities that produce Stryker chassis and mission packages. The extra Double V Hull A1 Stryker work is...

Detailed price information for General Dynamics Corp (GD-N) from The Globe and Mail including charting and trades.

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

Why Stryker’s new Foot & Ankle push matters for shareholders Stryker (SYK) is putting fresh attention on its Foot & Ankle franchise, rolling out new planning tools and limb reconstruction hardware at the 2026 AOFAS meeting in Seattle. The spotlight is on Prophecy Surgical Planning, now linked to the Incompass Total Ankle System, and on the Hoffmann LRF smartHEX platform, which extends the company’s reach into complex deformity correction supported by mobile software. Set against this product...

Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...

SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.

Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it will showcase new advancements across its Foot & Ankle portfolio at the 2026 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Seattle, including the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX.

Stryker has seen its share price slide sharply over the past year, and the question now is whether the current valuation still lines up with the cash the business is expected to generate. For investors watching the stock after recent headlines, the focus has shifted from past returns to whether today's price fairly reflects those underlying cash flows. The stock has fallen 24.5% over the past year, which puts the spotlight on whether that move has brought the valuation closer to what its...

Stryker's share price declined significantly due to operational issues, valuation concerns, and weaker orthopedic procedure volume growth. Learn more about SYK stock here.

Stryker (SYK) stock drops, sending rival Zimmer Biomet (ZBH) also lower as CFO warns of continued pressure in vascular and orthopedics segments. Read more here.

When temps drop, there’s nothing better than a steaming hot beverage especially when camping and the Camp Chef Stryker outperforms JetBoil every time

Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events &

Stryker Corporation (NYSE:SYK) signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio upon closing. FiberLocker is designed to reinforce rotator-cuff repairs by strengthening the connection between a surgical patch and tendon tissue. The transaction remains subject to customary closing conditions, while the purchase price […]

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Stryker (NYSE:SYK) and the best and worst performers in the medical devices & supplies - diversified industry.

Stryker (NYSE:SYK) received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro in a clinical setting. The company reported completion of the first surgical procedure using SportSuite Vision in an operating room environment. The software introduces augmented reality and spatial computing tools into surgical workflows and operating room visualization. The authorization marks a regulatory milestone for Stryker in mixed reality applications for healthcare. This...

Stryker has considerably underperformed the broader market over the past year, while analysts remain bullish on its future prospects.

Stryker stock has delivered a modest total return over the past five years, while the current intrinsic value estimate from a Discounted Cash Flow (DCF) framework suggests the shares trade at a discount to that internal calculation. At the same time, market based valuation multiples point to pricing that is broadly in line with peers, which leaves investors weighing two different valuation signals. Stryker has returned about 23.3% over the past five years, which points to a measured long...

Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.The FiberLocker System is a soft tissue augmentation technology designed to red

Stryker, a global leader in medical technologies, announced a strategic partnership with the Indian Association of Gynaecological Endoscopists (IAGE) to strengthen surgeon education and capabilities in fluorescence-guided surgery (FGS) in gynaecology. This strategic partnership was signed during the Pelvic Organ Prolapse Conference 2026 in Chennai, in the presence of 350 gynaecological surgeons and healthcare professionals from across India.

Investors need to pay close attention to SYK stock based on the movements in the options market lately.

Stryker’s sales unit in Michigan previously secured a US$100.00 million contract modification from the U.S. Defense Logistics Agency, underscoring its role as a key supplier to government healthcare and logistics systems. This award highlights the importance of stable government contracting as a complement to Stryker’s hospital and surgical product revenue mix. We’ll now examine how this sizable Defense Logistics Agency contract influences Stryker’s investment narrative, particularly its...

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Stryker (SYK) is back in focus after its Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. See our latest analysis for Stryker. For context, Stryker’s share price has been volatile around recent news, with a 4.17% 1 month share price return and a 5.88% decline year to date, while the 1 year total shareholder return is down 13.98%, the 3 year total shareholder return is up 23.40%, and...

Detailed price information for Wendys Company (WEN-Q) from The Globe and Mail including charting and trades.

Despite its disappointing performance relative to the broader market over the past year, Stryker continues to enjoy strong backing from Wall Street.

Shares of medical technology company Stryker (NYSE:SYK) jumped 2.7% in the afternoon session after its Stryker Sales unit in Michigan won a $100 million contract modification from the US Defense Logistics Agency.